We granted the Japan license for our innovative cardiac regeneration medicine to Daiichi Sankyo in May 2016. Daiichi Sankyo undertakes all development, regulatory and commercial activities for our immunomodulatory progenitor cells in the territory of Japan only, while we retain worldwide rights outside of Japan and global manufacturing responsibilities.
Innovative Cardiovascular Medicines Collaboration
Celixir has formed the Innovative Cardiovascular Medicines Collaboration. The Collaboration includes world-leading expertise in cardiac research and clinical development, with the purpose of better understanding the basis for cardiac regeneration.
The Collaboration will be jointly led by Professor Kim Fox, Consultant Cardiologist and Professor of Cardiology at Imperial College and Professor Sir Martin Evans, Nobel Laureate and Chief Scientific Officer of Celixir.
Support will be provided by Professor John Pepper, OBE, Interim Director of Research at the Royal Brompton and Harefield NHS Foundation Trust, together with Dr. Sabena Sultan, Global Head of Research at Celixir.
“Collaborations with world-class research physicians are critical in accelerating the development of innovative medicines. We're delighted to be forming this partnership with Professors Fox and Pepper, to advance Celixir’s investigational myocardial regeneration medicine and provide future innovations that will hopefully transform patients’ lives”, said Ajan Reginald, CEO, Celixir.
The first priority for the Collaboration will be investigating heart failure with an initial focus on developing insights into the regeneration of cardiac tissue. The Collaboration has been formed with the view of bringing new, life-saving medicines to heart failure patients.
TMC Life Sciences and Thomson Medical
Celixir has formed a partnership with TMC Life Sciences Bhd (TMCLS) and its associated company, Thomson Medical (Thomson) to accelerate the discovery and development of life-changing and life-altering regenerative medicines. Under the terms of the Memoranda of Understanding (MOU), Celixir will develop educational programmes to train medical professionals in regenerative medicine in partner hospitals (TMCLS and Thomson). In turn TMCLS and Thomson will provide access to a pan-Asia development, clinical trials and hospital network.
Celixir will expand its epigenetic research in heart failure and Kawasaki disease within the Southeast Asian patient population and aims to conduct clinical trials in Malaysia and Singapore.